Drugs / KB001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00691587 | Apr 2008 → Mar 2009 | Pseudomonas aeruginosa infectious disease | Humanigen, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00638365 | Mar 2008 → Mar 2009 | cystic fibrosis | Humanigen, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00638365 ↗ |
| Known as | Humaneered | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109536 ↗ |
| Action | Inhibit | “KB001 is a PEGylated, recombinant, anti-Pseudomonas-PcrV antibody Fab' fragment that blocks the function of Pa TTSS.” PMID 24019259 ↗ Sep 2013 |
| Modality | Monoclonal antibody | “KB001, a monoclonal antibody” NCT00638365 ↗ |
| Route | Intravenous | “Single-dose, 3mg/kg or 10mg/kg dose administered intravenously” NCT00638365 ↗ |